产品详情
靶点信息
In vitro | DMSO | 56 mg/mL (184.05 mM) | |
Water | Insoluble | ||
Ethanol | 56 mg/mL (184.05 mM) | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 32.86 mL | 164.31 mL | 328.62 mL |
0.5 mM | 6.57 mL | 32.86 mL | 65.72 mL |
1 mM | 3.29 mL | 16.43 mL | 32.86 mL |
5 mM | 0.66 mL | 3.29 mL | 6.57 mL |
*The above data is based on the productmolecular weight 304.3 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10893 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 304.3 |
Formula | C15H12O7 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 480-18-2 |
Synonyms | Dihydroquercetin, Taxifoliol, Distylin, Catechin hydrate, (+)-Taxifolin, trans-Dihydroquercetin, (+)-Dihydroquercetin |
SMILES | C1=CC(=C(C=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O |
产品标签
Product Questions
Product Questions
Brivanib (BMS-540215)
Brivanib (BMS-540215)是一种VEGFR-2抑制剂,IC50为25 nM,Ki为26 nM。
Pazopanib (GW-786034)
Pazopanib (GW-786034)是VEGFR-1,VEGFR-2,VEGFR-3,PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂,可阻…
Imatinib (Gleevec)
Imatinib (Gleevec)是一种多靶点酪氨酸激酶抑制剂,抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6,0.1和0.1 μM。
Telatinib (BAY 57-9352)
Telatinib (BAY 57-9352)是一种口服的血管内皮生长因子受体2和3(VEGFR2/3)和血小板衍生的生长因子受体β酪氨酸…
TPT-260 (Dihydrochloride)
TPT-260是噻吩硫脲衍生物。
Bibf1120 (Nintedanib)
Bibf1120 (Nintedanib)是一种新型的三联血管激酶抑制剂,可同时抑制三种生长因子受体:VEGFR,PDGF和FGFR。